Adverum Biotechnologies, Inc. (ADVM)

Adverum Biotechnologies' stock has trended up by 85.07% in the past six months, though it experienced a 32.14% decrease over the last year. In May 2025, the stock experienced an 11.15% return in the first week, despite a previous decline, and the company reported a $126 million cash position. In June 2025, the stock was down over 51% in the six months leading up to June 2025. In August 2025, Adverum reported its second-quarter financial results, announced that enrollment for its ARTEMIS Phase 3 trial was exceeding expectations, and announced a $10 million private placement with Frazier Life Sciences. By September 2025, Adverum announced the completion of screening for its pivotal Phase 3 ARTEMIS trial ahead of schedule. In October 2025, Eli Lilly and Co. announced its intent to acquire Adverum Biotechnologies. In November 2025, Adverum reported its Q3 2025 earnings, and analyst ratings included a consensus "Hold" rating, with some downgrades.

Adverum Biotechnologies, Inc. is a clinical-stage company without marketed products or services, so traditional demand seasonality is not applicable. The company's revenue is primarily derived from collaborations and licensing activities related to its gene therapy programs. Stock performance may show seasonality, but this relates to market trends, not product demand.

Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company focused on developing treatments for ocular diseases. Their lead product candidate is ixoberogene soroparvovec (Ixo-vec), a gene therapy in Phase 3 trials for wet AMD and Phase 2 for diabetic macular edema. Adverum is also developing BGTF-027 for blue cone monochromacy and aims to establish gene therapy as a new standard of care.

Adverum Biotechnologies, Inc. is headquartered in Redwood City, California, and is primarily US-based for its ARTEMIS Phase 3 study. The company plans a second global Phase 3 study (AQUARIUS) for wet AMD, indicating international expansion. Ixo-vec has received PRIME designation from the EMA and the Innovation Passport from the MHRA, highlighting international regulatory progress. Clinical trial locations include sites across the United States and Puerto Rico.

Adverum Biotechnologies' brand reputation is primarily tied to its scientific advancements, clinical trial results, and corporate governance. The company emphasizes its mission to establish gene therapy as a new standard of care and its core values. Its reputation is likely influenced by the progress and outcomes of its clinical trials, particularly for Ixo-vec, and its strategic collaborations.

Adverum Biotechnologies, Inc. has a mixed ownership structure. Approximately 23.91% of the company's stock is owned by Institutional Investors, 22.11% by Insiders, and 53.98% by Public Companies and Individual Investors. Major institutional owners include BML Capital Management, LLC, Frazier Life Sciences Management, L.P., Principia Wealth Advisory, LLC, TCG Crossover Management, LLC, and Vanguard Group Inc. Braden Michael Leonard owns the most shares among individuals, and hedge funds hold 15% of Adverum Biotechnologies' shares.